Ok, I am now abit confused, but also very pleased.
Reading over Alteritys last shareholder news letter released in January. I must have misread this section, but ATH434 has already been given orphan drug designation for the treatment for MSA.
Therefore, would I be correct in saying that this drug will be given the green light even if results remain the same/replicated from the 202 study in the 201 study ?.
Thoughts and/or further insight would be appreciated.
Ok, I am now abit confused, but also very pleased.Reading over...
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
-0.001(25.0%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.3¢ | $32.63K | 10.83M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 28 | 21801548 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 130971725 | 28 |
View Market Depth
| Last trade - 16.10pm 03/10/2024 (20 minute delay) ? |
| ATH (ASX) Chart |